Back to Search
Start Over
Sage Therapeutics, Biogen report results from Phase 2 study of SAGE-324
- Source :
- The Fly. July 24, 2024
- Publication Year :
- 2024
-
Abstract
- Sage Therapeutics (SAGE) and Biogen (BIIB) announced topline results from the Phase 2 KINETIC 2 dose-range study of the oral investigational drug SAGE-324 as a potential treatment in essential tremor. [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.802424391